



IFW

CT2777A US - CIP [1]

CERTIFICATE OF MAILING

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Nancy S. Turover
Type or print name

Signature

10/02/2005
Date

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF
PRASAD CHATURVEDULA, et al.
APPLICATION NO: **10/729155**
FILED: **12/05/2003**
FOR: **CALCITONIN GENE RELATED PEPTIDE RECEPTOR ANTAGONISTS**

ART UNIT: **1624**
EXAMINER: **BALASUBRAMANIAN, V.**

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with 37 C.F.R. §1.56, applicant wishes to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

Pursuant to the OG Notice of August 5, 2003, for U.S. national applications filed after June 30, 2003, the requirement for submitting a copy of each cited U.S. patent and each cited U.S. patent application publication is waived, therefore, copies of the U.S. patent and U.S. patent publications are not submitted. However, applicant is willing to send copies of any or all of these references at the Examiner's request.

Some of the listed references were cited in a search report in corresponding PCT International applications. Copies of these references and the search reports are enclosed herewith.

Applicant believes this paper is being filed before the mailing date of a first Office Action on the merits, and so under 37 C.F.R. §1.97(b)(3) no fees are required. If a fee is

deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-3880 in the name of Bristol-Myers Squibb Company. An additional copy of this paper is enclosed.

Also, copies of the other cited references are enclosed herewith.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Bristol-Myers Squibb Company
Patent Department
P.O. Box 4000
Princeton, NJ 08543-4000

Respectfully submitted,



Shah R. Makujina
Attorney for Applicant
Reg. No. 41,174
Phone: 203-677-7268

Date: 9/30/2005

FORM PTO-1449
(REV. 7-85)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO. CT2777A-CIP


APPLICATION NO. 10/729,155

APPLICANT Chaturvedula, et al.

FILING DATE December 5, 2003 GROUP

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)



U.S. RELATED PATENT APPLICATIONS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	AA	60/624,655 [10243PSP]	03 Nov 2004	Chaturvedula, <u>et al.</u>			
	AB	60/678,099 [10243PSP2]	05 May 2005	Chaturvedula, <u>et al.</u>			
	AC	60/633,159 [10466PSP]	03 Dec 2004	Chaturvedula, <u>et al.</u>			
	AD	11/091,429 [10260NP]	28 Mar 2005	Degnan, <u>et al.</u>			
	AE						

U.S. PATENT APPLICATION PUBLICATIONS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	AF	US 2003/0139417 A1	24 Jul 2003	Eberlein, <u>et al.</u>			
	AG	US 2003/0212057 A1	13 Nov 2003	Rudolf, <u>et al.</u>			
	AH	US 2003/0236282 A1	12 Dec 2003	Hurnaus, <u>et al.</u>			
	AI	US 2004/0014679 A1	22 Jan 2004	Trunk and Weiler			
	AJ	US 2004/0076587 A1	22 Apr 2004	Kruss, <u>et al.</u>			
	AK	US 2004/0132716 A1	08 Jul 2004	Rudolf, <u>et al.</u>			
	AL	US 2004/0192729 A1	30 Sep 2004	Rudolf, <u>et al.</u>			
	AM	US2004/0204397 A1 [CT2777A-CIP]	14 Oct 2004	Chaturvedula, <u>et al.</u>			
	AN	US2004/0063735 A1 [CT2777NP]	01 Apr 2004	Chaturvedula, <u>et al.</u>			
	AO	US 2005/0153959-A1 [10114-NP]	14 Jul 2005	Luo, <u>et al.</u>			
	AP						

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	AQ						
	AR						

FORM PTO-1449
(REV. 7-85)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION


(Use separate sheets if necessary)

ATTY. DOCKET NO. CT2777A-CIP

APPLICATION NO. 10/729,155

APPLICANT Chaturvedula, *et al.*

FILING DATE December 5, 2003 GROUP



FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	APPLICANT	CLASS	SUB-CLASS	TRANSLATION	
							YES	NO
	AS	CA 2 387 613	10 May 2001	Boehringer Ingelheim Pharma			<input type="checkbox"/>	<input type="checkbox"/>
	AT	CA 2 503 455 [English translation of WO2004/037810, see "AX"]	22 Apr 2005	Boehringer Ingelheim Pharma			<input type="checkbox"/>	<input type="checkbox"/>
	AU	EP 1 227 090 A1	31 Jul 2002	Tadeca Chemical Industries,			<input type="checkbox"/>	<input type="checkbox"/>
	AV	WO 02/10140	7 Feb 2002	Societe De Conseils De Recherches Et D'Applications Scientifiques (S.C.R.A)			<input type="checkbox"/>	<input type="checkbox"/>
	AW	WO 03/104236 [CT2777-PCT]	18 Dec 2003	Bristol-Myers Squibb Co.			<input type="checkbox"/>	<input type="checkbox"/>
	AX	WO 2004/037810	6 May 2004	Boehringer Ingelheim Pharma			<input checked="" type="checkbox"/> [see "AT"]	<input type="checkbox"/>
	AY	WO 2004/082602 A2	30 Sep 2004	Merck & Co., Inc.			<input type="checkbox"/>	<input type="checkbox"/>
	AZ	WO 2004/082605 A2	30 Sep 2004	Merck & Co., Inc.			<input type="checkbox"/>	<input type="checkbox"/>
	BA	WO 2004/082678 A1	30 Sep 2004	Merck & Co., Inc.			<input type="checkbox"/>	<input type="checkbox"/>
	BB	WO 2004/083187 A1	30 Sep 2004	Merck & Co., Inc.			<input type="checkbox"/>	<input type="checkbox"/>
	BC	WO 2004/091514 A2	28 Oct 2004	Merck & Co., Inc.			<input type="checkbox"/>	<input type="checkbox"/>
	BD	WO 2004/092166 A2	28 Oct 2004	Merck & Co., Inc.			<input type="checkbox"/>	<input type="checkbox"/>
	BE	WO 2004/092168 A1	28 Oct 2004	Merck & Co., Inc.			<input type="checkbox"/>	<input type="checkbox"/>
	BF	WO 2005/056550 [10114-PCT]	23 Jun 2005	Bristol-Myers Squibb Co.			<input type="checkbox"/>	<input type="checkbox"/>
	BG							
	BH							

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

	BI	OLESEN, J. <i>et al.</i> , "Calcitonin Gene-Related Peptide Receptor Antagonist BIBN 4096 BS for the Acute Treatment of Migraine", <i>New England J. of Medicine</i> , 2004, 350 (11): 1104-1110
	BJ	PASTERNAK, et al., "Potent, orally bioavailable somatostatin agonists: good absorption achieved by urea backbone cyclization", <i>Bioorganic & Medicinal Chemistry Letters</i> , Oxford GB, Vol. 9, No. 3, 8 Feb 1999, 491-496

FORM PTO-1449
(REV. 7-85)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION


(Use several sheets if necessary)

ATTY. DOCKET NO. CT2777A-CIP

APPLICATION NO. 10/729,155

APPLICANT Chaturvedula, *et al.*

FILING DATE December 5, 2003 GROUP



BK	ROSENFELD, <i>et al.</i> , "Production of a novel neuropeptide encoded by the calcitonin gene via tissue-specific RNA processing", <i>Nature</i> , 1983, 304:129-135
BL	
BM	
BN	
BO	
EXAMINER	DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.